LR-90 Aromatic Derivative Suppresses RAGE Expression and AGE Accumulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Advanced glycation end products (AGEs) and their receptors contribute to diabetic complications, atherosclerosis, and inflammatory disorders by promoting tissue damage and inflammation, with existing inhibitors having limitations in effectively suppressing AGE formation and RAGE expression.
Innovation Solution
The compound LR-90, a novel aromatic derivative, is administered to suppress RAGE expression and inhibit AGE accumulation, thereby reducing pro-inflammatory signals and genes like NADPH oxidase, COX-2, and MCP-1, effectively addressing diabetic complications and atherosclerosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If existing AGE inhibitors are used, then AGE formation is suppressed, but RAGE expression is not effectively suppressed
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of AGE inhibitors to create compound LR-90, which has enhanced dual functionality. The molecular parameters of the inhibitor are changed to enable simultaneous suppression of both AGE formation and RAGE expression, resolving the limitation of existing single-function inhibitors.
Solution Approach 2:
Compound LR-90 is designed with multi-functionality, serving both as an AGE formation inhibitor and a RAGE expression suppressor. This universal compound addresses multiple pathological pathways simultaneously, overcoming the limitation of existing inhibitors that only target AGE formation without affecting RAGE expression.
2Object-generated harmful factors
If RAGE expression is suppressed, then inflammatory gene expressions are reduced, but existing methods lack efficacy
Solution Approach 1:
The patent uses compound LR-90 as an intermediary substance that mediates between AGE accumulation and inflammatory response. By suppressing RAGE expression through this intermediary compound, the inflammatory gene expressions (NADPH oxidase, COX-2, MCP-1) are effectively reduced, establishing a reliable suppression pathway.
Solution Approach 2:
The compound LR-90 exerts preliminary anti-action by suppressing RAGE expression before the inflammatory cascade is fully activated. This preemptive suppression prevents the downstream inflammatory gene expressions from occurring, thereby effectively reducing inflammatory responses in diabetic complications.
3Object-affected harmful factors
If AGE accumulation is inhibited, then tissue damage is reduced, but existing inhibitors have limitations
Solution Approach 1:
The patent develops compound LR-90 as a composite chemical entity combining multiple functional groups that work synergistically. The composite structure includes moieties for AGE inhibition and RAGE suppression, creating a more effective and reliable inhibitor compared to simpler existing compounds with limited effectiveness.
Solution Approach 2:
The compound LR-90 can be viewed as segmented functional units where one segment targets AGE formation inhibition and another segment targets RAGE expression suppression. This segmentation of functional activities within a single compound enhances overall effectiveness in preventing tissue damage through multiple mechanisms.
Data Source
AI summary
Accelerated formation of advanced glycation/lipoxidation end products (AGEs/ALEs) has been implicated in the pathogenesis of various diabetic complications. Several natural and synthetic compounds have been proposed and tested as inhibitors of AGE/ALE formation. We have previously reported the therapeutic effects of several new AGE/ALE inhibitors on the prevention of nephropathy and dyslipidemia in streptozotocin (STZ)-induced diabetic rats. In this study, we investigated the effects of various concentrations of LR-90 on the progression of renal disease and its effects on AGE and receptor for AGE (RAGE) protein expression on the kidneys of diabetic STZ-rats. In vitro studies were also performed to determine if LR-90 could inhibit the expression of various pro-inflammatory mediators in human monocytic cells.